SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    F. Huang, H. Zhang, M. Wu, H. Yang, M. Kudo, C. J. Peters, P. G. Woodruff, O. D. Solberg, M. L. Donne, X. Huang, D. Sheppard, J. V. Fahy, P. J. Wolters, B. L. M. Hogan, W. E. Finkbeiner, M. Li, Y.-N. Jan, L. Y. Jan, J. R. Rock, Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction, Proceedings of the National Academy of Sciences, 2012, 109, 40, 16354

    CrossRef

  2. 2
    Karin Lanthaler, Elizabeth Bilsland, Paul D Dobson, Harry J Moss, Pınar Pir, Douglas B Kell, Stephen G Oliver, Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast, BMC Biology, 2011, 9, 1, 70

    CrossRef

  3. 3
    Fernando Perez-Ruiz, Samuel Hernandez-Baldizon, Ana M. Herrero-Beites, Miguel A. Gonzalez-Gay, Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout, Arthritis Care & Research, 2010, 62, 9
  4. 4
    Michael P. Keith, William R. Gilliland, Kathleen Uhl, Pharmacology and Therapeutics, 2009,

    CrossRef

  5. 5
    Fernando Perez-Ruiz, Nicola Dalbeth, Naomi Schlesinger, Febuxostat, a novel drug for the treatment of hyperuricemia of gout, Future Rheumatology, 2008, 3, 5, 421

    CrossRef

  6. 6
    Frédéric Lioté, Thomas Bardin, Traitement de la goutte, Revue du Rhumatisme, 2007, 74, 2, 160

    CrossRef

  7. 7
    Ted R. Mikuls, Kenneth G. Saag, Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?, Current Rheumatology Reports, 2005, 7, 3, 242

    CrossRef

  8. 8
    F. Pérez-Ruiz, Tratamiento hipouricemiante en la gota: mitos y evidencias, Reumatología Clínica, 2005, 1, 3, 139

    CrossRef

  9. 9
    Ted R. Mikuls, Catherine H. MacLean, Jason Olivieri, Fausto Patino, Jeroan J. Allison, John T. Farrar, Warren B. Bilker, Kenneth G. Saag, Quality of care indicators for gout management, Arthritis & Rheumatism, 2004, 50, 3
  10. 10
    Michael Alderman, Kala J. V. Aiyer, Uric acid: role in cardiovascular disease and effects of losartan, Current Medical Research and Opinion, 2004, 20, 3, 369

    CrossRef

  11. 11
    Fernando Perez-Ruiz, Marcelo Calabozo, Jose I. Pijoan, Ana M. Herrero-Beites, Ana Ruibal, Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout, Arthritis Care & Research, 2002, 47, 4
  12. 12
    Susumu Watanabe, John Kanellis, Takahiko Nakagawa, Lin Han, Ryuji Ohashi, Hui Lan, Lili Feng, Richard J Johnson, Reducing uric acid as a means to prevent cardiovascular and renal disease, Expert Opinion on Therapeutic Patents, 2002, 12, 2, 193

    CrossRef

  13. 13
    Alastair J.J. Wood, Bryan T. Emmerson, The Management of Gout, New England Journal of Medicine, 1996, 334, 7, 445

    CrossRef

  14. 14
    U. Gresser, N. Zöllner, Uricosuric effect of irtemazole in healthy subjects, Klinische Wochenschrift, 1989, 67, 19, 971

    CrossRef

  15. 15
    H. Breithaupt, M. Tittel, Kinetics of allopurinol after single intravenous and oral doses, European Journal of Clinical Pharmacology, 1982, 22, 1, 77

    CrossRef